Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations

Abstract Background Based on the CAPItello-291 phase III trial results, capivasertib in combination with fulvestrant has been approved for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer harboring one or more PIK3CA, AKT1, and/or PTEN...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Moumita Chaki, Mona Benrashid, Subir Puri, Smruthy Sivakumar, Ethan S. Sokol, Josefa M. Briceno, Neil Vasan
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2025-07-01
Цуврал:	Breast Cancer Research
Нөхцлүүд:	AKT inhibitor Capivasertib Targeted therapy Breast cancer Next-generation sequencing Circulating tumor DNA
Онлайн хандалт:	https://doi.org/10.1186/s13058-025-02055-0
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!